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Abstract
Background: The zinc finger transcription factor Egr-1 (Early growth response 1) is central to several growth
factors and represents an important activator of target genes not only involved in physiological processes like
embryogenesis and neonatal development, but also in a variety of pathophysiological processes, for example
atherosclerosis or cancer. Current options to investigate its transcription and activation in vivo are end-point
measurements that do not provide insights into dynamic changes in the living organism.
Results: We developed a transgenic mouse (Egr-1-luc) in which the luciferase reporter gene is under the control of
the murine Egr-1 promoter providing a versatile tool to study the time course of Egr-1 activation in vivo.I n
neonatal mice, bioluminescence imaging revealed a high Egr-1 promoter activity reaching basal levels three weeks
after birth with activity at snout, ears and paws. Using a model of partial hepatectomy we could show that Egr-1
promoter activity and Egr-1 mRNA levels were increased in the regenerating liver. In a model of wound healing,
we demonstrated that Egr-1 promoter activity was upregulated at the site of injury.
Conclusion: Taken together, we have developed a transgenic mouse model that allows real time in vivo imaging
of the Egr-1 promoter activity. The ability to monitor and quantify Egr-1 activity in the living organism may
facilitate a better understanding of Egr-1 function in vivo.
Background
The transcription factor Egr-1 belongs to the Egr family
(Egr-1 to -4) of zinc finger proteins [1,2]. The growth
factor inducible gene was discovered after stimulation of
neuronal cells with nerve growth factor (NGF) and
therefore initially referred to as NGF inducible A
(NGFI-A) [3]. Fibroblast growth factor 1 (FGF-1), plate-
let derived growth factor (PDGF), vascular endothelial
growth factor (VEGF) and general serum proteins are
also capable of activating Egr-1 (for a recent review see
[4]). Egr-1 is an important activator of target genes such
as angiopoetin 1 [5] or cell division cycle 20 gene
(cdc20) [6], which in turn are key players in cell prolif-
eration, migration and differentiation [5,6]. Furthermore,
Egr-1 itself has been shown to promote haematopoietic
cell differentiation towards the macrophage lineage [7,8].
Being in the crossfire of different growth signals makes
Egr-1 an interesting candidate to be studied during
embryogenesis and neonatal development [9]. In addi-
tion, Egr-1 has been associated with atherosclerosis [10],
diabetes [11], wound healing [12] and tumor growth
[13]. Although Egr-1 knockout mice are viable, liver
regeneration after hepatectomy is decreased due to
impaired progression of mitosis [6]. Hence, Egr-1 relates
to various physiological and pathological processes.
However, most of the gathered data on Egr-1 gene acti-
vation have been evaluated within in vitro studies and
could not be confirmed when being re-evaluated in in
vivo models [4]. For this reason, it is inevitable to study
activation patterns in the living organism over time. In
knockout mice, however, compensation of Egr-1 loss of
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excluded (Pagel et al, manuscript submitted). Since
dynamic changes over time cannot be examined by end-
point measurements, studying Egr-1 activity within the
living organism could help in gaining new information
on in vivo Egr-1 gene activation.
The firefly luciferase has been applied as a biolumines-
cent reporter in living mice using a photon imaging sys-
tem for studying gene induction noninvasively [14]. We
have established a transgenic mouse model using the
murine Egr-1 promoter to control the expression of the
luciferase reporter and utilized noninvasive biolumines-
cence imaging (BLI) to study the dynamics of Egr-1
gene activity in the same animal over time. This model
was applied to analyze Egr-1 promoter driven luciferase
expression during the development of neonatal mice
between the ages of 7 to 21 days after birth, where we
observed a continuous decrease in Egr-1 promoter activ-
ity over time within the examined areas (snout and
paw). The activation pattern of Egr-1 during wound
healing and tissue regeneration was followed in a model
for wound healing of ear tissue and in liver regeneration
after partial liver hepatectomy.
Results & Discussion
The Egr-1 promoter sequence was cloned into the plas-
mid pUHC13-2 replacing the CMV promoter in the
CMV-Luc expression cassette. Transgenic mice were
established by microinjecting the plasmid into male pro-
nuclei of murine zygotes and transferred into pseudo-
pregnant females (strain C57BL/6). For the Egr-1-
luciferase (Egr-1-luc) construct seven founder animals
were obtained. Breeding of founder animals with
C57BL/6 wildtype mice led to an establishment of two
lines (L1 and L2), which were further propagated. Egr-1-
luc transgenic mice were viable and healthy and showed
a normal life span, indicating no serious malformation
due to the presence of the transgene. Breeding capabil-
ities were also normal with a litter size of 5-8 pups. To
show functional expression of luciferase, adult Egr-1-luc
mice were injected with the luciferase substrate luciferin
and the activity monitored in anaesthetized animals
(Figure 1). In the living animal, highest signal intensities
were observed in regions around the snout (especially
lips), ears and paws, whereas in the fur covered regions
the luciferase signal was not detectable, which could
also be due to quenching effects. It can be postulated
that these anatomical regions are still undergoing more
developmental changes, i.e. cell proliferation than other
areas of the body, such as the continued growth of the
teeth. For example, Egr-1 has been identified to be
involved in periodontal regeneration [15].
To analyze exemplarily whether primary cells from
Egr-1-luc mice might also be suitable for in vitro
investigations, we isolated vascular smooth muscle cells
(SMC) from adult Egr-1-luc mice, cultured them and
measured luciferase activity in cell lysates. On average,
4,000 RLU were measured per well (12-well plate, luc-
negative cells give a background value of <300 RLU/
well). This Egr-1 promoter activity in proliferating in
vitro cultures of SMC is in line with Egr-1 activities
described in the literature for SMC [16]. As the major
aim of this work was to monitor Egr-1 activity in vivo,
we did not further pursue in vitro cultures.
In vivo monitoring of Egr-1 promoter activity during
postnatal development and embryogenesis
To monitor expression of the reporter during postnatal
d e v e l o p m e n t ,E g r - 1 - l u ct r a n s g e n i cm i c ew e r ei m a g e da t
day 7, 10, 13, 16, 19 and 21 after birth as described in
“Methods”. Day 7 was the earliest date, when intraperi-
toneal (i.p.) injections of thea n e s t h e t i ca n dl u c i f e r a s e
were tolerated. Animals from the same litter were mea-
sured for luciferase activity on indicated dates and were
kept with the parents between the measurements to
ensure feeding by lactating mother animals. For lucifer-
ase signal quantification we used defined regions of
interest (ROI), which were placed over the snout and
paw. Due to the lack of hair growth within those
regions, which can otherwise reduce the luciferase signal
and interfere with signal quantification, we did not
expect a signal quenching. Other areas at the ventral
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Figure 1 Luciferase activity in adult Egr-1-luc mice.T r a n s g e n i c
Egr-1-luc mice (4 month old, male or female) were anaesthetized
with isofluorane in oxygen and received 6 mg luciferin in 100 μl
PBS by i.p. injection. Ten minutes after injection BLI measurement
was carried out (1 min signal collection, setting ‘high resolution’). A
representative animal is shown. The reflected light picture is
overlaid by a a liacolor coded BLI image visualized in ‘blend mode’,
which allows allocating the BLI signal to the respective areas shown
in the underlying reflected light picture.
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Page 2 of 11side of the body were excluded from quantitative analy-
sis, as due to the onset of hair growth, the BLI signal
c a nb ec o n s i d e r a b l yq u e n c h e d .T h et o t a ln u m b e ro f
photons collected per area was normalized to back-
ground levels by subtraction of the total counts per area
measured in a similar sized ROI placed over a back-
ground area. As shown in Figure 2A, at day 7 after birth
mice showed strong luciferase activity throughout the
entire ventral side of the body. A clear reduction of luci-
ferase activity within the areas of paws, snout, ears and
tail was observed during their development throughout
the following 2 weeks. All other areas, where the onset
of fur growth leads to signal quenching, were excluded
from further analysis. When quantifying the luciferase
signal in ROIs at paw (Figure 2B) and snout (Figure
2C), luciferase activity was found to be reduced over
time reaching 30% or 40%, respectively, at day 21 com-
p a r e dt ot h ev a l u ea td a y7 .T oi n v e s t i g a t e ,w h e t h e r
there is remaining Egr-1-luc activity in fur-covered
regions of adult mice, an adult mouse was sacrificed ten
minutes after luciferase injection, the body cavity
opened and the skin partially removed from the ventral
area. Immediately thereafter BLI analysis was started
(additional file 1). Besides Egr-1-luc activity at the snout
area (as already shown in Figures 1 and 2A), there was
remaining activity within the exposed skin, but not in
other organs like liver or in muscle tissue. Hence, for
multiple BLI measurements over time, rather superficial
areas, like skin can be analyzed in living animals,
whereas low luciferase signals within internal organs
might be outshined by the skin activity of Egr-1 driven
luciferase.
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Figure 2 Egr-1 promoter driven luciferase activity during postnatal development (day 7 - 21 after birth). Luciferase activity in Egr-1-luc
mice at indicated age was measured by BLI after i.p. injection of luciferin. The luciferase signal was collected for 10 sec from the ventral side of
the mice (n = 6).A: A reflected light picture of representative animals at indicated age is overlaid by a color coded BLI image. B and C:
Luciferase activity was quantified within regions of interest (ROIs) placed at the paw (B) or snout area (C) and expressed as photons per second
per cm
2 to correct for size differences in ROI size at different ages. A background ROI of similar size was subtracted. Median values of six animals
+ standard deviation are shown. * p < 0.05, *** p < 0.001; indicated day vs. day 7, Wilcoxon test.
Dussmann et al. BMC Developmental Biology 2011, 11:28
http://www.biomedcentral.com/1471-213X/11/28
Page 3 of 11We also evaluated Egr-1 promoter activity in trans-
genic and nontransgenic embryos on day E14 of devel-
opment (Theiler Stage 22) by immunohistochemical
analysis of luciferase and Egr-1 (Figure 3). In accordance
with the BLI data, bone primordia of hind limbs stained
positive for luciferase (Figure 3A). Various neuronal
structures demonstrated luciferase staining, among them
the sympathetic paravertebral ganglia (Figure 3B).
Furthermore, an intense immunoreactivity was detected
at the masticatory apparatus, especially at the area of
the palatal shell (Figure 3C); snout and whisker follicles
showed only weak staining (data not shown). Wildtype
(non-transgenic) animals did not display any positive
staining (Figure 3D-F). When staining sections with Egr-
1 antibody, a pattern corresponding to the previously
described endogenous Egr-1 expression [9], was
observed. The strong luciferase positive staining at the
palatal shell of the masticatory apparatus, which has not
been described before, could also be well correlated to
Egr-1 expression (Figure 3G). The pattern of Egr-1 pro-
moter activity (developing limbs, central nervous system,
mandibles) is at least in part similar to the pattern of
ERK signaling during embryogenesis, where major sites
of ERK activity were observed, besides others, in limb
buds, forebrain and the frontonasal process [17], which
points at the interconnection between ERK and Egr-1
signaling. Our data clearly demonstrate that Egr-1 is
highly upregulated throughout the body during neonatal
development, where we observed maximal activity at
day seven after birth, the earliest time point measured
(Figure 2). Similar observations were made with trans-
genic mice expressing vascular endothelial growth factor
promoter driven luciferase in neonatal mice [18], and
maximal activity was observed one week after birth fol-
lowed by a continuous decline in activity. When stimu-
lating endothelial cells in vitro with VEGF, TNFa or
thrombin, activation of Egr-1 was observed, although
the induction of Egr-3 was more profound [19]. Hence,
we postulate that there appears to be a spatial and tem-
poral correlation between VEGF and Egr-1 activity dur-
ing neonatal development. VEGFR-2 promoter
controlled luciferase expression was analyzed in a simi-
lar way in neonatal mice [20]: at the earliest time point
measured (2 weeks after birth) highest luciferase activity
was found throughout the entire body, whereas in 6
week old mice the signal was about 100-fold reduced
and remained constant for up to 15 weeks after birth. In
our study, Egr-1 promoter controlled luciferase activity
reached baseline levels already three weeks after birth
indicating a faster decrease compared to VEGFR-2. In
vitro studies showed the interconnection of VEGF and
Egr-1, as in endothelial cells VEGF stimulation led to
initially high Egr-1 levels [21]. Besides VEGF, other
growth factors upregulated in neonatal organisms, such
as FGF-1 and -2 can activate Egr-1 [22], whereas the
decrease in Egr-1 activity can be explained by the nega-
tive feedback loop of Egr-1, which can bind to its own
promoter [21] leading to a ‘fine tuning’ of its activity.
Apparently Egr-1 is involved in the cell proliferation
process during postnatal growth. The activity of Egr-1 is
on a high level almost all over the entire ventral anat-
omy of the neonatal mouse and decreases until reaching
a baseline activity when mice are fully grown. During
this stage, the only significant Egr-1 activity was
observed at the paws, snout, ears, and tail, which is in
line with observations made while measuring VEGFR-2
promoter driven luciferase [20]. It still has to be deter-
mined, which specific processes are taking place on
these sites of high Egr-1 promoter activity relative to the
rest of the body.
Egr-1 activation in regenerating liver
Liver hepatectomy in rodents leads to induction of cell
division in the majority of hepatocytes 1-2 days after
surgery [23,24]. Here we used in vivo BLI to monitor
the activity of the Egr-1 promoter in the transgenic Egr-
1-luc mice 48 h (n = 6 and n = 3 control) and 72 h (n
= 4 and n = 3 control) following 1/3 hepatectomy. For
quantification, ROIs were placed over the areas of
regenerating liver tissue close to the primary excision
s i t e .T h eh i g h e s tE g r - 1a c t i v i t yw a so b s e r v e da tr e g i o n s
directly adjacent to the original sectioning wound with
some elevated activity at the edges of the liver lobes, as
shown in Figure 4A. When quantifying the BLI signal
within the area next to the excision site, an up to 12-
fold signal increase was observed compared to sham
operated animals, both at 48 h and 72 h after surgery
(Figure 4B). After hepatectomy, clusters of cells stained
positive for luciferase (Figure 5A) and for Egr-1 (Figure
5B) in a similar pattern in sections of liver tissue at the
site of surgery.
To obtain a quantitative view on Egr-1 levels during
liver regeneration, animals were sacrificed 12 h or two
days after surgery and liver tissue homogenized for
mRNA and protein quantification of Egr-1 and lucifer-
ase, respectively (Figure 6). Twelve hours after surgery,
mRNA levels of Egr-1 were six times higher compared
to the sham operated group (Figure 6A). For luciferase,
the mRNA level was not detectable in the sham oper-
ated group, whereas in hepatectomized mice, a strong
signal was found. Analyzing protein levels two days after
surgery, an increased signal was found for both Egr-1
and luciferase (Figure 6B). Compared to Egr-1 this
increase was more pronounced for luciferase, which can
be explained by the fact that luciferase protein has a
considerably longer intracellular half live (3 hours, [25])
than Egr-1 protein, which is more rapidly degraded (half
live <2 h, [26]). The involvement of Egr-1 in liver
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Figure 3 Immunohistochemical analyses of luciferase and Egr-1 expression during embryonic development. Egr-1-luc (A, B, C and G)
and wildtype (D, E and F) C57BL/6 embryos on day E14 of development were stained for luciferase protein (A-F) or Egr-1 protein (G). In bone
primordia of hindlimbs (A), sympathetic paravertebral ganglia (B) and masticatory apparatus (C) luciferase positive areas (arrows) are stained in
lilac in transgenic embryos, in wildtype embryos no luciferase signal was detected (D-F). When staining for Egr-1 protein, a similar pattern of
protein expression was found - exemplarily shown for the masticatory apparatus (G) - as for luciferase (C); scale bar: 50 μm.
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Page 5 of 11regeneration has been first described by Mueller and
colleagues [27], and Egr-1
-/- mice showed significantly
delayed liver regeneration after hepatectomy [6]. The
importance of Egr-1 expression in liver injury has also
been described in ethanol induced fatty liver, where Egr-
1 promoted TNFa expression [28]. In our liver regen-
eration experiments, we have demonstrated that luci-
ferin expression was induced at the early stages of liver
regeneration. Already 12 h after surgery, mRNA levels
of luciferase and Egr-1 were strongly elevated (Figure 6),
which is in line with results obtained in rats [27]. Inter-
estingly, luciferase activity and protein levels were ele-
vated both at 48 h and 72 h after surgery (Figures 4
and 6). During the regeneration of liver tissue, quiescent
liver cells re-enter the cell cycle and divide until the ori-
ginal liver mass is restored [23]. Besides induction of
proliferation, partial hepatectomy can lead to local
hypoxia and upregulation of hypoxia inducible factor 1a
(HIF-1a) [29]: peak levels of HIF-1a were observed at
24 h after surgery, whereas peak levels of VEGF
appeared at later time points. Hence, the induction of
Egr-1 after partial hepatectomy can be at least in part
due to hypoxic conditions, an effect already described
for macrophages in vitro, where hypoxia induced Egr-1
expression occurred [30]. Even though the major Egr-1
promoter activity was observed in the area of the initial
surgery wound, which is mainly due to the wound heal-
ing process, some elevated activity was seen at the edges
of the lobes suggesting the onset tissue regeneration by
the means of cell division and proliferation. These
results support the reported findings on impaired mito-
sis in Egr-1 deficient mice [6] and evidence that Egr-1 is
not only induced within the healing process, but also
during other processes where cell division and prolifera-
tion is involved.
Egr-1 activation in wound healing
Using in vivo BLI, we monitored the activity of the Egr-
1 promoter in Egr-1-luc mice immediately after the
infliction of a punch wound on the right ear. For quan-
tification we used defined ROIs (please note: color scale
in Figure 7 is on an approx. 10-fold lower level than in
Figure 2A). The Egr-1 activity showed a major increase
in the immediate vicinity surrounding the wound, while
the more distant areas did not show any difference com-
pared to the control ear (Figure 7A). Placing a ROI over
the area surrounding the wound, a >12-fold increased
BLI signal was found 24 h after infliction of the wound
when compared to a similar sized ROI on the adjacent
control ear (Figure 7B). At the early stages of wound
healing, an inflammatory response followed by re-
epithelialization of the wound area and establishment of
granulation tissue with accompanying neovascularization
occurs [31]. Due to the interaction of Egr-1 and inflam-
matory cytokines, like TNFa [28,32] and others, Egr-1 is
involved in the wound healing process. In Egr-1 null
mice, wound healing and the influx of inflammatory
cells was shown to be significantly reduced, whereas
Egr-1 over expression led to exuberant tissue repair and
enhanced collagen production [12]. Our data of the ear
wound experiment suggest that Egr-1 plays a substantial
role in the wound healing process, as its activity
increased around the immediate wound area.
Conclusion
In summary, the present study followed the Egr-1 acti-
vation pattern over time in the transgenic Egr-1-luc ani-
mal model and showed the spatial expression patterns
and their time dependent changes in vivo.T h i st r a n s -
genic mouse provides a convenient model for studying
Egr-1 expression during neonatal development and
wound healing at areas were the fur of mice with
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Figure 4 Egr-1 promoter driven luciferase activity after partial
liver hepatectomy. A: BLI of sham operated (left) or
hepatectomized (right) Egr-1-luc mice at 48 h (top row) and 72 h
(bottom row) after surgery. Representative animals from n = 3-6 are
shown. Red arrows denote the site of initial surgery, arrowhead
points at the edge of a liver lobe showing luciferase activity. B:
Quantitative luciferase signals from ROIs placed over the liver area
of sham operated or hepatectomized mice 48 h or 72 h after
surgery. A representative background ROI of comparable size was
subtracted to account for background activity. n = 3-6; mean values
of six animals + standard deviation are shown. *p < 0.05 sham vs.
hepatectomy (U-test, Mann-Whitney).
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Page 6 of 11C57Bl/6 background does not interfere with BLI ima-
ging. Monitoring Egr-1 activity within internal organs,
such as in the liver regeneration model presented, was
only possible by endpoint measurements with animals
having an opened body cavity. To further improve its
usability for BLI, cross-breeding into hairless mice will
improve its sensitivity. Moreover, it will then offer a
useful tool for monitoring effects of pharmaceutical
drugs over time in vivo.
Methods
Transgenic mice (Egr-1-luc)
Cloning strategy
The vector containing the murine Egr-1 promoter was a
generous gift from Martin Braddock (Glaxo Wellcome,
United Kingdom). From this vector, the Egr-1 promoter
[33] compassing the sequence from -930 to +237 base
pairs relative to the Egr-1 promoter transcriptional start
site [34,35] was isolated by SalI restriction. 5’ends were
filled-in with DNA polymerase I (Klenow enzyme) and
cloned into the pUHC13-2 vector by blunt end ligation
thereby replacing the CMV promoter. The pUHC13-2
vector, which was a generous gift from H. Bujard
(ZMBH, Germany), is a derivate of pUHD10-1 [36] and
was originally developed by U. Baron in the laboratory
of H. Bujard. In short, the reporter plasmid pUHC13-2
containing the promoter-enhancer sequence of the
CMV promoter followed by a polylinker and the lucifer-
ase gene of Photinus pyralis (firefly) fused to the SV40
small-t intron and poly(A) signal was digested with
HindIII and XhoI to excise the CMV promoter. The
5’ends were filled in with Klenow enzyme and ends
were dephosphorylated with alkaline phosphatase. After
cloning the Egr-1 promoter into pUHC13-2 vector, the
Egr-1 promoter - luciferase reporter gene - SV40 small-t
intron fragment was isolated by AseI and PvuI digestion.
Finally the transgene was purified using a QIAquick Gel
Extraction Kit (Qiagen). All constructs obtained were
reviewed and verified by sequencing.
Establishing Egr-1-luc transgenic mouse lines
Egr-1-luc transgenic mice were established by micro-
injecting 2 pl of the transgene (5 ng/μl) into male pro-
nuclei (identified by size) of murine zygotes and trans-
ferred into pseudopregnant females (strain C57BL/6).
The presence of the transgene was confirmed by means
of PCR using a specific primer combination spanning
the region between the reporter gene luciferase and the
SV40 small-t intron (forward primer: 5’- GAG ATC
GTG GAT TAC GTC GC - 3’; reverse primer: 5’-T G C
TCC CAT TCA TCA GTT CC -3’).
In vivo imaging of luciferase activity
Animals were housed in individually vented cages with a
12 h day/night cycle and chow and water provided ad
libitum. All animal procedures were approved and con-
trolled by the local ethics committee and carried out
according to the guidelines with the German law for
protection of animal life.
In vivo imaging was performed using the IVIS Lumina
Imaging System (Caliper Life Sciences GmbH) as
A (luc) B (Egr-1)
Figure 5 Immunohistochemical analyses of Egr-1 driven luciferase expression in regenerating liver. Egr-1-luc mice 4-8 weeks of age were
subjected to one third liver hepatectomy as described in “Methods”. Forty-eight hours after surgery mice were sacrificed, liver tissue fixed in PFA
and stained for luciferase (luc). Tissue next to the site of surgery (rim upper left corner in both images) is shown and cells staining positive for
luciferase (A) as well as Egr-1 (B) appear as clusters with brown-reddish staining (arrows; scale bar: 50 μm)
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Page 7 of 11recently described [37]. For the developmental studies,
E g r - 1 - l u ct r a n s g e n i cm i c ew e r ea n e s t h e t i z e db yi . p .
injection of xylazin/ketamin (0.375 ml/0.635 ml in PBS,
respectively); for liver regeneration and wound healing
studies animals were anaesthetized with 2.5% isofluorane
in oxygen. Ten minutes after i.p. injection of 300 mg/kg
luciferin (Promega, Hilden, Germany) the biolumines-
cence signal was collected for one to three minutes.
Reflected light pictures were taken during illumination
with four white LED. Image acquisition and processing
was carried out using Living Image 2.60.1 - IGOR Pro
4.09 Software.
Immunohistochemistry
For immunhistochemical detection of luciferase and Egr-
1 in liver, the tissue was fixed in 4% paraformaldehyde
(PFA) over night at 4°C and subsequently embedded in
paraffin. Embryos (n = 6, littermates) were collected at
day 14 of development for detection of luciferase and
Egr-1, fixed in 4% PFA for three days and placed in a
solution of Na4EDTA (ethylenediaminetetraacetic acid
tetrasodium salt), 200 g/L, pH 7.1 (adjusted using 20% w/
v citric acid) for decalcification before being embedded.
Four μm sections were mounted on Super Frost
® Plus
slides (Thermo Scientific Gerhard Menzel). Antigen
retrieval for luciferase staining was achieved with Pronase
E (Sigma-Aldrich) diluted in 0.5 M Tris buffer (0.1% w/v)
for 20 min at room temperature; Egr-1 antigen retrieval
was performed in a steamer with sodium citrate buffer
(10 mM sodium citrate, pH 6.0) for 20 min. Endogenous
peroxidase activity was quenched by treatment with 1%
H2O2 for 30 min. Slides were incubated over night at 4°C
with an anti-luciferase goat polyclonal horseradish
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Figure 6 mRNA and protein levels of Egr-1 and luciferase after
partial hepatectomy. Egr-1-luc mice were subjected to one third
hepatectomy or sham operation, sacrificed 12 h (A)o r4 8h( B) after
surgery and liver tissue subjected to mRNA analyses by qRT-PCR (A)
or Western blot analyzing protein levels of Egr-1 and luciferase (B).
A: mRNA levels of Egr-1 and luciferase, respectively (average relative
mRNA levels relative to 18S rRNA levels); mRNA levels of luciferase
in sham operated animals were below the detection limit. n = 4,
mean values + standard deviation are shown; *p < 0.05 sham vs.
hepatectomy (U-test, Mann-Whitney). B: Representative Western
blots showing the protein levels of Egr-1, luciferase and b-actin for
sham operated (left panel) or hepatectomized animals (right panel),
respectively; data from two representative animals per treatment are
shown. Numbers indicate relative luciferase and Egr-1 expression
calculated from optical densities (OD) of luciferase, Egr-1 and ß-actin
protein bands. n = 4, mean values + standard deviation are shown;
*p < 0.05 sham vs. hepatectomy (U-test, Mann-Whitney).
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Figure 7 In vivo bioluminescence imaging of the ear wound.I n
Egr-1-luc mice between the ages of 4-8 weeks an ear wound was
inflicted in one ear. Twenty-four hours after infliction animals were
subjected to BLI. Luciferase signal was collected for 2 min from the
wounded or the control ear, respectively. A: Color coded BLI image
overlaid onto a reflected light image from the control ear (left) or
wounded ear (right) immediately (top row) or 24 h (bottom row)
after wound infliction. B: Quantitative luciferase signals from ROIs
placed over the wound site or a similar sized ROI at the control ear.
n = 3, mean values + standard deviation are shown; *p < 0.05
control vs. wound (U-test, Mann-Whitney).
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Page 8 of 11peroxidase (HRP) conjugated antibody (Abcam, 1:50 in
Tris-buffered saline (TBS)/0.3% BSA (TBS-B)) and an
Egr-1 rabbit monoclonal antibody (clone: 15F7, # 4153,
Cell Signaling, dilution 1:50 in TBS-B), respectively. For
Egr-1 staining, a biotinylated secondary anti-rabbit anti-
body was prepared using a rabbit ABC kit (VECTAS-
TAIN
® Elite ABC system, Vector). Immunoreactivity was
visualized with the chromogen 3-amino-9-ethyl-carba-
zole (AEC) (AEC single solution, Invitrogen) for 20 min.
One-third liver hepatectomy
Hepatectomy was carried out based on a currently pub-
lished protocol [24] with slight modifications. In brief,
mice were anaesthetized with isoflurane and 50 μl car-
profen given i.p. for pain reduction. All surgical steps
were carried out as described [24], except that only the
median lobe was resected leaving a small ischemic
stump behind. After surgery, mice received daily 50 μl
carprofen i.p.. In sham operated animals, only the mid-
line incision was performed and sutured. At indicated
time points after surgery, animals were anaesthetized,
the liver was exposed after luciferin injection and images
of the ventral view of the fully exposed liver were
collected.
Ear wound healing model
A punch wound of approximately 1.5 mm in diameter
was inflicted with an ear notcher on one ear of Egr-1-
luc mice according to the standard procedure of animal
labeling. At indicated time points after the wound set-
ting, BLI from the ear region was carried out as
described above, only that the ear was immobilized with
adhesive tape during imaging. As a control, the
untreated ear was measured.
Cell culture
Primary cultures of murine aortic SMC were established
as previously described [38] and cultured on gelatin-
coated plates with standard HAM’sF 1 2 / W a y m o u t h1 : 1
medium (Biochrom), 10% FCS (fetal calf serum) and
antibiotics (100 U/ml penicillin, 100 μg/ml streptomycin,
0.25 μg/ml amphotericin B). For stimulation, cells
between passages three and four were serum starved for
two days. Luciferase quantification was performed in
cell lysates as described [39]. In brief, an aliquot of cell
lysate was quantified in a tube luminometer after injec-
tion of substrate solution for 10 sec, background values
from wildtype cells were deducted from the measure-
ment; two nanogram recombinant luciferase (Promega,
Mannheim, Germany) correspond to 10
7 relative light
units (RLU).
RNA isolation and quantitative Real Time PCR (qRT-PCR)
Total RNA was isolated according to the procedure of
Chromzynski and Sacchi [40] from frozen liver samples
isolated 12 h after hepatectomy or sham operation (n =
4). One microgram of DNase treated total RNA was
reverse transcribed using random nonamers (Roche) and
a 1st Strand cDNA Synthesis Kit for RT-PCR (Roche).
qRT-PCR was performed with a Light Cycler 1.5
(Roche) in a reaction volume of 10 μlu s i n gaL i g h t
Cycler
® FastStart DNA Master
Plus SYBR Green I Kit
(Roche) and 50 pmol of each primer (Egr-1, forward: 5’-
CGA ACA ACC CTA TGA GCA CCT G - 3’;r e v e r s e :
5’- CAG AGG AAG ACG ATG AAG CAG C - 3’;l u c i -
ferase, forward: 5’- CAG ATG CAC ATA TCG AGG
TG - 3’; reverse: 5’- CAT ACT GTT GAG CAA TTC
ACG - 3’;1 8 Sr R N A ,f o r w a r d :5 ’- GGA CAG GAT
TGA CAG ATT GAT AG - 3’; reverse: 5’-C T CG T T
CGT TAT CGG AAT TAA C - 3’). Three independent
qRT-PCR reactions were performed on each template.
An initial denaturation step at 95°C for 10 min was fol-
lowed by 40 cycles of denaturation (95°C, 10 sec),
annealing (64°C for Egr-1; 58°C for luciferase, 64°C for
18S rRNA, 5 sec), and extension (72°C, 15 sec). Melt
curve analyses were performed to control specific ampli-
fication. Results were normalized to the expression
levels of the 18S rRNA.
Western blot
Protein extracts of liver tissue samples were isolated 48
h after hepatectomy as described [41]. Equal amounts
of protein were separated on a 4-20% Tris-glycine gel
(Serva) and immunoreactive bands were visualized
using Super-Signal-Femto-West (Pierce) with a HRP
conjugated rabbit polyclonal antibody against firefly
luciferase (1:1000, Santa Cruz Biotechnology), a rabbit
monoclonal antibody against Egr-1 (1:500, Cell Signal-
ing) or b-actin (1:2000, Sigma), respectively. Lumines-
cence was evaluated using Hamamatsu 1394 ORCA-
ERA camera, AequoriaMDSTM Macroscopic Imaging
System and Wasabi software (Hamamatsu Photonics,
Herrsching, Germany). Protein bands were quantified
by densitometry, and results expressed as Luc/ß-actin
and Egr-1/ß-actin ratio, respectively. For negative con-
trol, the first antibody was omitted. Blots were
repeated at least twice.
Statistics
Statistical analyses were performed using WinStat. p-
values <0.05 were regarded as statistical significant and
calculated using either the non-parametric U-test
(according to Mann-Whitney) or the Wilcoxon test.
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Page 9 of 11Additional material
Additional File 1: BLI of adult Egr-1-luc mice with opened body
cavity. Transgenic Egr-1-luc mice (one month old) received 6 mg
luciferin in 100 μl PBS by intraperitoneal injection. Ten minutes thereafter
the animal was killed by cervical dislocation, the body cavity opened
immediately, skin from the ventral side partially removed and BLI
measurement was carried out (10 min signal collection, setting ‘high
resolution’). A representative animal is shown with similar amplification
setting as in Figure 2A.
Abbreviations
Egr-1: Early growth response 1; Luc: luciferase; CMV: cytomegalovirus; SMC:
vascular smooth muscle cells; RLU: relative light units; i.p.: intraperitoneal;
ROI: region of interest; BLI: bioluminescence imaging
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